BridgeBio Oncology Therapeutics, Inc. (BBOT) - Net Assets
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has net assets worth $411.10 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($448.38 Million) and total liabilities ($37.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BridgeBio Oncology Therapeutics, Inc. (BBOT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $411.10 Million |
| % of Total Assets | 91.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BridgeBio Oncology Therapeutics, Inc. - Net Assets Trend (2021–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore BridgeBio Oncology Therapeutics, Inc. assets under control for the complete picture of this company's asset base.
Annual Net Assets for BridgeBio Oncology Therapeutics, Inc. (2021–2025)
The table below shows the annual net assets of BridgeBio Oncology Therapeutics, Inc. from 2021 to 2025. For live valuation and market cap data, see BridgeBio Oncology Therapeutics, Inc. (BBOT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $411.10 Million | +117.84% |
| 2024-12-31 | $188.72 Million | +296969.04% |
| 2023-12-31 | $-63.57K | -190.57% |
| 2022-12-31 | $-21.88K | -19.18% |
| 2021-12-31 | $-18.36K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BridgeBio Oncology Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35652364300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.00% |
| Other Comprehensive Income | $16.00K | 0.00% |
| Other Components | $767.64 Million | 186.73% |
| Total Equity | $411.10 Million | 100.00% |
BridgeBio Oncology Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Bukopin Tbk
JK:BBKP
|
$671.50 Million |
|
Arvinas Inc
NASDAQ:ARVN
|
$672.23 Million |
|
Advanced Nano Products Co. Ltd
KQ:121600
|
$672.32 Million |
|
MTY Food Group Inc
TO:MTY
|
$672.49 Million |
|
Fujian Rongji Software Co Ltd
SHE:002474
|
$671.02 Million |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
$671.00 Million |
|
2G Energy AG
XETRA:2GB
|
$670.96 Million |
|
Hubei Xiangyuan New Material Technology Inc.
SHE:300980
|
$670.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BridgeBio Oncology Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 188,716,681 to 411,096,000, a change of 222,379,319 (117.8%).
- Net loss of 134,044,000 reduced equity.
- New share issuances of 22,222,000 increased equity.
- Other comprehensive income increased equity by 16,000.
- Other factors increased equity by 334,185,319.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-134.04 Million | -32.61% |
| Share Issuances | $22.22 Million | +5.41% |
| Other Comprehensive Income | $16.00K | +0.0% |
| Other Changes | $334.19 Million | +81.29% |
| Total Change | $- | 117.84% |
Book Value vs Market Value Analysis
This analysis compares BridgeBio Oncology Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $8.39 | x |
| 2022-12-31 | $0.00 | $8.39 | x |
| 2023-12-31 | $0.00 | $8.39 | x |
| 2024-12-31 | $11.34 | $8.39 | x |
| 2025-12-31 | $13.20 | $8.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BridgeBio Oncology Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-32.61%) is below the historical average (-14.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-41.52K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.33K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-64.69 Million |
| 2024 | -39.36% | 0.00% | 0.00x | 1.03x | $-93.15 Million |
| 2025 | -32.61% | 0.00% | 0.00x | 1.09x | $-175.15 Million |
Industry Comparison
This section compares BridgeBio Oncology Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | $411.10 Million | 0.00% | 0.09x | $671.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more